ArticleEuropean radiology2026
Deep learning model using contrast-enhanced CT for predicting overall survival in oropharyngeal squamous cell carcinoma: a prospective multicenter study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAccurate risk stratification for overall survival (OS) in patients with oropharyngeal squamous cell carcinoma (OPSCC) is critical for guiding personalized treatment and surveillance. A deep learning (DL) model was developed and validated to estimate OS in OPSCC patients based on contrast-enhanced computed tomography (CECT). MATERIALS AND
methodsA total of 269 patients from three centers were retrospectively enrolled and divided into training (n = 144), internal validation (n = 56), and external validation (n = 69) cohorts. An additional prospective cohort (n = 50) was used for HPV-based subgroup analysis. Clinical and semantic CT features were selected via multivariate Cox regression. Radiomic features were extracted using PyRadiomics. A Swin Transformer V2-based DL model was developed to estimate OS risk. SHAP values and Grad-CAM were used to assess model interpretability. Combined models were constructed by integrating clinical factors, handcrafted radiomics features, and DL score values. Predictive accuracy and clinical utility of the model were evaluated through C-index, time-dependent ROC analysis, calibration assessment, and decision curve analysis. Kaplan-Meier analysis was performed based on the optimal cutoff identified by the X-tile.
resultsDeep learning-clinical signature (DLCS) achieved the best performance, with C-indices of 0.856 (internal) and 0.783 (external). It provided accurate 1-, 3-, and 5-year OS predictions, robust calibration, and clinical benefit. DLCS effectively stratified patients into high- and low-risk groups and maintained predictive consistency across HPV subgroups.
conclusionsThe CECT-based DLCS offers reliable OS prediction and risk stratification in OPSCC, supporting individualized clinical decision-making and precision oncology. KEY POINTS: Question Prognostic prediction in OPSCC is crucial for personalized treatment, yet existing clinical tools lack accuracy and non-invasiveness. Findings The DLCS integrates imaging and clinical data to achieve precise OS prediction and robust risk stratification in OPSCC. Clinical relevance The DLCS offers a novel, non-invasive, and accurate prognostic tool for OPSCC, enabling differentiation between high- and low-risk patients. This supports personalized treatment strategies and optimizes clinical decision-making.
Indexed as
Identifiers
41196362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.